INTRODUCTION
Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory neurological disease of the central nervous system (CNS)
MS destroys the myelin and the axons in various myelinated CNS neurons to varying degrees
The course of MS is unpredictable: in most patients, initial episodes of reversible neurological deficits are often followed by progressive neurological deterioration Daclizumab is a humanized monoclonal antibody targeting the α subunit (CD25) of the interleukin 2 (IL-2) receptor (IL-2R)
It is said to have the potential to restore the homeostasis between autoimmunity and autotolerance that is a feature of MS Daclizumab reduced relapse risk, disease activity as monitored by MRI, and risk of confirmed disability worsening in many pivotal RCTs
Daclizumab was approved for use in the US and in the European Union as a oncemonthly subcutaneous (SC) injection for the treatment of RMS in May & July 2016
The mechanism of action of Daclizumab in MS are thought to be the following:
I t reduces the expansion of proinflammatory, activated T lymphocytes It simultaneously promotes autotolerance through the expansion of CD56 natural killer (NK) cells,
It partially preserves the regulatory T cell (T REG ) population and function
Daclizumab was associated with modest increases in mild-to-moderate severity hepatic disorders, cutaneous events, and infections; these were manageable with routine medical care, and did not appear to increase with extended treatment Literature search was conducted in Cochrane library and Clinicaltrials.gov databases from inception An initial search using the MeSH Terms "daclizumab", "multiple sclerosis", and "Randomized Controlled Trials" was followed by a search of related citations All randomised controlled trials (RCTs) comparing daclizumab with placebo for the treatment of RRMS were included In addition, references of the included studies were screened for additional studies Four authors independently screened titles, abstractsand subsequently the full texts of all the potentially relevant studies. The same four authors extracted data and assessed risk of bias using the modified Jadad scale.
The main outcome was safety in terms of various adverse events at 52 weeks
MATERIALS AND METHODS
Our findings demonstrated that incidence of any adverse event with Daclizumab was comparable with placebo However, Daclizumab was associated with more infections and cutaneous events during the treatment of RRMS, when compared with placebo Further high quality trials are needed to establish the safety of Daclizumab in RRMS A total of four RCTs involving 3286 RRMS patients were included in this metaanalysis.
RRMS patients received 150 mg or 300 mg Daclizumab via subcutaneous route.
Overall, the risk of bias of included trials was low 
